tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Paul Choi, 36 are a SELL (20.11%), 68 are a HOLD (37.99%), 75 are a BUY (41.9%).
Analyst Paul Choi, currently employed at GOLDMAN SACHS, carries an average stock price target met ratio of 61.44% that have a potential upside of 34.67% achieved within 139 days.
Paul Choi’s has documented 370 price targets and ratings displayed on 38 stocks. The coverage is on Healthcare, Pharmaceuticals sectors.
Most recent stock forecast was given on PHAT, Phathom Pharmaceuticals at 09-Aug-2024.
Analyst best performing recommendations are on SBTX (SILVERBACK THERAPEUTICS ).
The best stock recommendation documented was for VIR (VIR BIOTECHNOLOGY) at 3/1/2021. The price target of $61 was fulfilled within 1 day with a profit of $5.73 (8.59%) receiving and performance score of 85.87.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$3
$1.84 (158.62%)
$3
1 months 28 days ago
(26-Sep-2024)
0/4 (0%)
$2.42 (417.24%)
Hold
$7
5 months 3 days ago
(20-Jun-2024)
1/3 (33.33%)
$0.45 (6.87%)
57
Sell
$1
$-0.16 (-13.79%)
$1.5
10 months 6 days ago
(17-Jan-2024)
6/6 (100%)
$-0.02 (-1.96%)
278
Buy
11 months 5 days ago
(18-Dec-2023)
1/1 (100%)
$32.69 (83.16%)
358
Buy
$9
$7.84 (675.86%)
1 years 6 months 12 days ago
(11-May-2023)
2/4 (50%)
$4.84 (116.35%)
178
Which stock is Paul Choi is most bullish on?
Which stock is Paul Choi is most reserved on?
What Year was the first public recommendation made by Paul Choi?
